Aimmune on track for EU submission of peanut allergy therapy

A week after Aimmune said an FDA decision on approval of its peanut allergy therapy may come a month late, the company said Monday its timeline for an MAA submission remains on schedule following a successful readout from a Phase III trial conducted in Europe.

Aimmune Therapeutics Inc. (NASDAQ:AIMT) plans to submit an MAA to EMA for AR101 in mid-2019...